As of June 6, 2025, Lattice Biologics Ltd (LBL.V) reports a Current Ratio of 0.12.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Lattice Biologics Ltd's Current Ratio
Over recent years, Lattice Biologics Ltd's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2020-09-30 | 0.12 |
| 2019-09-30 | 0.14 |
| 2018-09-30 | 0.24 |
| 2017-09-30 | 0.32 |
| 2016-09-30 | 0.36 |
This gradual decrease highlights how Lattice Biologics Ltd manages its short-term assets and liabilities over time.
Comparing Lattice Biologics Ltd's Current Ratio to Peers
To better understand Lattice Biologics Ltd's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Lattice Biologics Ltd (LBL.V) | 0.12 |
| Constellation Pharmaceuticals Inc (CNST) | 14.05 |
| PZ Wind Down Inc (PZRXQ) | 7.99 |
| Phio Pharmaceuticals Corp (PHIO) | 5.65 |
| Globeimmune Inc (GBIM) | 2.62 |
| Protalix Biotherapeutics Inc (PLX) | 2.34 |
Compared to its competitors, Lattice Biologics Ltd's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.